IGM Biosciences merges with Concentra Biosciences for $1.247 per share.

IGM Biosciences, a biotech company, has entered into a definitive merger agreement with Concentra Biosciences, acquiring IGM Biosciences for $1.247 per share in cash plus a non-tradeable contingent value right. The CVR represents the right to receive excess closing net cash of $82.0 million and 80% of any net proceeds from the disposition of certain product candidates and intellectual property within one year following closing. The IGM Biosciences Board of Directors has unanimously approved the agreement.

Mountain View, Calif., July 01, 2025 — IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company specializing in engineered IgM-based therapeutic antibodies, has entered into a definitive merger agreement with Concentra Biosciences, LLC. Under the terms of the agreement, Concentra will acquire IGM Biosciences for $1.247 in cash per share, plus a non-tradeable contingent value right (CVR).

The CVR entitles shareholders to receive 100% of IGM Biosciences' closing net cash exceeding $82.0 million and 80% of any net proceeds from the disposition of certain product candidates and intellectual property within one year following the closing of the merger. The IGM Biosciences Board of Directors has unanimously approved the agreement, which is expected to close in August 2025.

Concentra will commence a tender offer by July 16, 2025, to acquire all outstanding shares of IGM Biosciences' common stock. The merger is subject to certain conditions, including the tender of voting common stock representing at least a majority of the total number of outstanding shares of voting common stock, the availability of at least $82.0 million of cash (net of transaction costs and other liabilities at closing), and other customary closing conditions.

The acquisition reflects challenging market conditions in the biotech sector and indicates that IGM Biosciences' primary value lies in its cash reserves rather than its pipeline or technology platform. The CVR structure suggests that Concentra is primarily acquiring IGM Biosciences for its cash position while providing shareholders potential upside if assets generate value.

This deal structure is a common occurrence when a biotech company has faced significant operational challenges. The $1.247 per share cash offer represents an extremely low valuation for a clinical-stage biotech company, further underscoring the financial difficulties IGM Biosciences has faced.

IGM Biosciences and Concentra have engaged Wilson Sonsini Goodrich & Rosati, P.C. and Gibson, Dunn & Crutcher LLP as legal counsel, respectively. The merger agreement and related transactions are expected to be filed with the U.S. Securities and Exchange Commission (SEC) shortly.

Investors and shareholders are urged to read the tender offer materials, including the offer to purchase, letter of transmittal, and related documents, which will be available on the SEC's website at www.sec.gov upon commencement of the offer.

References:
[1] https://www.globenewswire.com/news-release/2025/07/01/3108348/0/en/IGM-Biosciences-Enters-into-Agreement-to-Be-Acquired-by-Concentra-Biosciences-for-1-247-in-Cash-per-Share-Plus-a-Contingent-Value-Right.html
[2] https://www.stocktitan.net/news/IGMS/igm-biosciences-enters-into-agreement-to-be-acquired-by-concentra-8nmixujjvxee.html